Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.
Wedbush Maintains Outperform on Foghorn Therapeutics, Raises Price Target to $20
Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.
Related Posts
Bitcoin, Ethereum Record Losses; FTX Token Becomes Top Loser
Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices falling below the $43,000 level on Monday.
Ethereum (CRYPTO: ETH) also recorded losses, trading below the key $2,300 mark this morning.
Citigroup Initiates Coverage On Expensify with Buy Rating, Announces Price Target of $25
Citigroup analyst Steven Enders initiates coverage on Expensify (NASDAQ:EXFY) with a Buy rating and announces Price Target of $25.
Elon Musk And Twitter Continue Talks On Closing Deal, May Have Agreement As Early As Wednesday
- Reuters Citing Source